Steppingstones: Four Milestones On The Path To Neurological Cell Therapy

By Ole Isacson, MD-Ph.D., founding Director of the Neuroregeneration Research Institute at McLean Hospital, Professor of Neurology (Neuroscience) at Harvard Medical School, Professor of Neurology at Massachusetts General Hospital, Biorasi Scientific Advisory Board Member

Industry professionals have touted cell therapy and regenerative medicine as the future of clinical research and patient treatment. Over the next seven years, the cell therapy market is expected to grow by $100 billion. While the research is not necessarily new – clinicians have been exploring the use of cells to prolong life and make “necessary repairs” to the human body for quite some time.

“A degrading body is a fundamental truth,” noted Dr. Ole Isacson, founding Director of the Neuroregeneration Research Institute at McLean Hospital, Professor of Neurology (Neuroscience) at Harvard Medical School, Professor of Neurology at Massachusetts General Hospital, and Biorasi Scientific Advisory Board Member.

“Pioneering physicians and clinicians have realized this inevitability and worked towards the goal of using the body’s building blocks (cells) to combat debilitating diseases. And with stem cell therapy expanding into Parkinson’s Disease and other neurological illnesses, it is important to look back on these early milestones of cell therapy in light of these new developments in clinical research.”

Look back on how the industry has arrived at neurological cell therapy solutions by exploring the stem cell steppingstones – from blood transfusions to Parkinson’s Disease treatments.